Blackstone Group Inc. is buying the consumer health-care business of Japan’s Takeda Pharmaceutical Co. for ¥242 billion ($2.29 billion), one of the larger private-equity acquisitions in a country where such deals are slowly expanding. Takeda has been pushing ahead with a plan to divest $10 billion of assets to pay down debt it incurred from the $58 billion acquisition of Shire PLC last year. The drugmaker has said it wants to focus on prescription drugs.

Source: Wall Street Journal August 24, 2020 11:40 UTC